期刊文献+

高三尖杉酯碱联合伊马替尼对K562/G01细胞的作用及机制研究

Effect of Homoharringtonine Combined with Imatinib on the K562/G01 Cells and Its Mechanism
下载PDF
导出
摘要 目的:探索高三尖杉酯碱(Homoharringtonine,HHT)联合伊马替尼(Imatinib,IM)对K562/G01细胞增殖、凋亡的影响及其可能的作用机制。方法:应用CCK-8法检测HHT联合IM对K562/G01细胞增殖的影响,流式细胞术检测细胞的凋亡率及磷酸化酪氨酸水平,Western blot检测P210及PI3K/Akt信号通路相关蛋白的表达水平。结果:HHT联合IM与单药相比,对K562/G01细胞的增殖活性具有明显抑制作用(P<0.05),细胞的凋亡率显著增加(P<0.05);HHT与IM联合可显著抑制K562/G01细胞内的p-Tyr及p-Crkl的表达水平,并能使p210蛋白及其下游通路蛋白P13K和p-Akt的表达水平明显降低。结论:HHT联合IM可协同抑制K562/G01细胞增殖并诱导其凋亡,其机制可能与抑制p210蛋白表达及其激酶活性有关。 Objective:To explore the effect of homoharringtonine(HHT) combined with imatinib(IM) on proliferation and apoptosis of K562/G01 cells and its potential mechanism.Methods:K562/G01 cells were cultured with HHT and/or IM.CCK-8 assay was used to detect cell proliferation.Cell apoptosis and phosphorylated tyrosine levels were analyzed by flow cytometry.The expression levels of p210,PI3 K,p-Akt and Akt protein were determined by Western blot.Results:Compared with HHT or IM alone,drug combination significantly inhibited cell proliferation and induced apoptosis of K562/G01 cells(both P 〈0.05).HHT combined with IM could inhibit the levels of phosphorylated tyrosine and phosphorylated Crkl and downregulate the expressions of p210,PI3 K and p-Akt in K562/G01 cells.Conclusion;HHT combined with IM can synergistically inhibit proliferation and induce apoptosis of K562/G01 cells by suppressing the p210 expression and its kinase activity.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2017年第1期80-84,共5页 Journal of Experimental Hematology
基金 新型临床诊疗技术攻关(HAS2015026)
关键词 高三尖杉酯碱 伊马替尼 磷酸化酪氨酸 K562/G01细胞 PI3K/AKT通路 homoharringtonine imatinib phosphorylated tyrosine K562/G01 cell P13K/Akt pathway
  • 相关文献

参考文献4

二级参考文献16

  • 1主鸿鹄,刘艳荣,秦亚溱,常艳,李金兰,阮国瑞,江滨,陈珊珊,陆道培.PY20抗体检测bcr-abl阳性细胞内磷酸化酪氨酸的临床应用[J].中华血液学杂志,2006,27(7):441-444. 被引量:2
  • 2Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood ,2000 ;96:3343 - 3356.
  • 3Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med, 2001; 7:228-234.
  • 4Kantarjian HM, Talpaz M, Cortes J, et al. Quantitative polymerase chain reaction monitoring of bcr-abl during therapy with imatini mesylate (ST1571 ; Gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res,2003 ; 9 : 160 - 166.
  • 5Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell, 2000; 103:211 -225.
  • 6Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood,2006 ; 108 : 28 - 37.
  • 7Hochhaus A, Lin F, Reiter A, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive pulymerase chain reaction. Blood, 1996; 87: 1549 - 1555.
  • 8Drobyski WR, Endean DJ, Klein JP, et al. Detection of BCR-ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. Br J Haematol,1997; 98:458 - 466.
  • 9Ferrell JE Jr. Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability. Curr Opin Cell Biol,2002 ; 14:140 - 148.
  • 10Lee MS, Chan KS, Freireich E J, et al. Detection of minimal residual bcr-abl transcripts by a modified polymerase chain reaction. Blood, 1988 ;72:893 - 897.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部